Recent:Dokukina.
Jan 13 |
et al., NCT07157007 | Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients |
| 14% improved recovery (p=0.01). Interim results showing improved time-to-sustained symptom alleviation and resolution with ratutrelvir. | ||